Semaglutide Side Effects: Ozempic, Wegovy and Rybelsus
Semaglutide side effects from FDA labels: nausea rates differ on Ozempic and Wegovy. Shared warnings, plus what users report. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
Semaglutide side effects are mainly gastrointestinal. Ozempic, Wegovy and Rybelsus are the same active ingredient, so the class of warnings overlaps, but trial rates are not interchangeable: the studies enrolled different people and used different labelled products. In the US Ozempic prescribing information (updated June 1, 2026), nausea occurred in 20.3% of people in the higher-strength weekly type 2 diabetes trial arm versus 6.1% on placebo. In the US Wegovy prescribing information (updated June 18, 2026), nausea occurred in 44% of adults in the weekly weight-reduction trials versus 16% on placebo. Those figures are how the labels reported results, not a dosing guide and not a head-to-head trial. Brand pages with the full tables: Ozempic side effects and Wegovy side effects. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
How trial rates differ by brand
The table below places label rates side by side only to show that the same molecule can look different in different programmes. Ozempic figures are from Table 1 of the US Ozempic label (placebo-controlled type 2 diabetes trials). Wegovy figures are from Table 3 of the US Wegovy label (pooled adult weight-reduction trials of the weekly injection). Last reviewed: November 11, 2026.
| Side effect | Ozempic higher-strength arm (diabetes trials) | Ozempic placebo | Wegovy arm (weight trials) | Wegovy placebo |
|---|---|---|---|---|
| Nausea | 20.3% | 6.1% | 44% | 16% |
| Vomiting | 9.2% | 2.3% | 24% | 6% |
| Diarrhoea | 8.8% | 1.9% | 30% | 16% |
| Constipation | 3.1% | 1.5% | 24% | 11% |
| Abdominal pain | 5.7% | 4.6% | 20% | 10% |
| Any gastrointestinal reaction | 36.4% | 15.3% | 73% | 47% |
| Stopped because of a GI reaction | 3.8% | 0.4% | 4.3% | 0.7% |
Rybelsus, the Wegovy pill, and compounded products
Rybelsus is oral semaglutide labelled for type 2 diabetes. On the Rybelsus side effects page, the Canadian monograph and matching US-label diabetes trials report nausea in 11.0% to 19.7% of people versus 6.4% on placebo. The US Wegovy label says common adverse reactions with the daily tablet were similar in type and frequency to the injection table above; details are on Wegovy pill. Compounded copies are not the approved branded products: compounded semaglutide.
Serious warnings that appear across labels
The US Ozempic and Wegovy labels carry a boxed warning about thyroid C-cell tumours seen in rodents. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other shared warnings include acute pancreatitis, gallbladder disease, dehydration-related kidney injury, hypoglycaemia when combined with insulin or a sulfonylurea, diabetic retinopathy complications, severe gastrointestinal reactions, hypersensitivity, and pulmonary aspiration during general anaesthesia or deep sedation. Both labels say the medicine is not recommended in people with severe gastroparesis. A rare optic-nerve condition, NAION, has been reviewed for semaglutide by regulators; see Ozempic and vision loss and Ozempic and thyroid cancer.
Severe ongoing abdominal pain, signs of dehydration, vision changes, symptoms of low blood sugar, a neck lump or trouble swallowing, or signs of an allergic reaction need medical care. This page summarises public label facts. It is not a substitute for the full prescribing information or a clinician's advice.
What anonymous users report here
Our semaglutide file is small: 37 published anonymous confessions as of mid-October 2026. That is a self-selected sample of stories, not a clinical rate. Live counts and phrase matches are on the Semaglutide hub, which is a confession data page, not this review. Related stories also appear on the semaglutide hub.
Related topics
related peptides:
community guides:
More confessions from the archive
Community Q&A
- What are the most common semaglutide side effects?
- Gastrointestinal effects are the most common on the US labels: nausea, vomiting, diarrhoea, constipation and abdominal pain. Rates are higher in Wegovy weight-management trials than in Ozempic diabetes trials. Those studies are not a head-to-head comparison.
- Are semaglutide side effects the same on Ozempic and Wegovy?
- They share the same active ingredient, so the class of warnings overlaps. Trial rates differ. See Ozempic side effects and Wegovy side effects for the label tables.
- Does Rybelsus have the same side effects?
- Rybelsus is oral semaglutide for type 2 diabetes. Its labels describe the same class of gastrointestinal effects and serious warnings. Nausea in the diabetes-trial range cited on our Rybelsus page was 11.0% to 19.7% versus 6.4% on placebo.
- Is the semaglutide side-effects report a clinical rate?
- No. That report is built from a small, self-selected sample of published anonymous confessions. Phrase-match percentages are not the chance that you will get an effect.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Sources
Last reviewed November 12, 2026. Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.